Boston Scientific Corporation [BSX] fell -7.67% so far this year. What now?


Boston Scientific Corporation [NYSE: BSX] slipped around -0.27 points on Friday, while shares priced at $39.22 at the close of the session, down -0.68%. The company report on May 20, 2022 that How Innovations in Medical Devices Are Allowing Physicians to Work Better – and Patients to Heal Quicker.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


New high-resolution imaging solutions from Boston Scientific are designed to provide a clearer view of the human anatomy.

Boston Scientific Corporation stock is now -7.67% down from its year-to-date (YTD) trading value. BSX Stock saw the intraday high of $39.57 and lowest of $38.24 per share. The company’s 52-week high price is 47.49, which means current price is +3.25% above from all time high which was touched on 04/20/22.

Compared to the average trading volume of 8.82M shares, BSX reached a trading volume of 12397590 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Boston Scientific Corporation [BSX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $50.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Truist have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 13, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on March 02, 2022, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $51, while RBC Capital Mkts analysts kept a Outperform rating on BSX stock.

The Average True Range (ATR) for Boston Scientific Corporation is set at 1.39, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 4.64. The Price to Book ratio for the last quarter was 3.35, with the Price to Cash per share for the same quarter was set at 0.23. Price to Free Cash Flow for BSX in the course of the last twelve months was 60.90 with Quick ratio for the last quarter at 0.80.

How has BSX stock performed recently?

Boston Scientific Corporation [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.11. With this latest performance, BSX shares dropped by -15.31% in over the last four-week period, additionally sinking by -4.83% over the last 6 months – not to mention a drop of -6.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 39.34, with the RSI for the last a single of trading hit 38.41, and the three-weeks RSI is set at 40.74 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 42.86, while it was recorded at 40.02 for the last single week of trading, and 43.00 for the last 200 days.

Boston Scientific Corporation [BSX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +16.17 and a Gross Margin at +62.76. Boston Scientific Corporation’s Net Margin is presently recorded at +8.75.

Return on Equity for this stock inclined to 6.51, with Return on Assets sitting at 3.30.

Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.20.

Earnings analysis for Boston Scientific Corporation [BSX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 10.27%.

Insider trade positions for Boston Scientific Corporation [BSX]

There are presently around $50,797 million, or 93.00% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 126,433,288, which is approximately 0.831% of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 113,364,827 shares of the stock with an approximate value of $4.45 billion in BSX stocks shares; and FMR LLC, currently with $3.65 billion in BSX stock with ownership of nearly -5.851% of the company’s market capitalization.

450 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 74,134,639 shares. Additionally, 378 investors decreased positions by around 77,396,530 shares, while 151 investors held positions by with 1,143,661,639 shares. The mentioned changes placed institutional holdings at 1,295,192,808 shares, according to the latest SEC report filing. BSX stock had 104 new institutional investments in for a total of 9,388,542 shares, while 80 institutional investors sold positions of 4,280,948 shares during the same period.